Optimizing Channel Strategy to Overcome CGT-Specific Barriers
Key Insights
In this session, Lattanzi addresses fundamental questions and best practices for building a robust channel strategy designed to navigate the unique challenges faced by CGT companies.
- Understanding patient pathways: This presentation emphasizes the importance of knowing where and how patients are currently being treated. Identifying the specialties involved and the existing therapeutic landscape is crucial for developing an effective channel strategy.
- Navigating logistical challenges: The discussion highlights the specialized storage needs for CGT products, such as maintaining appropriate temperatures for gene and cell therapies, and explains the importance of coordination among patients, manufacturers, and treatment facilities to ensure timely product administration.
- Clinical and business considerations: The complexities of administering CGT therapies, including adverse event management and reimbursement challenges, are explored. This session also provides insights into how to structure partnerships and payment terms that alleviate financial risks for treatment centers.
Watch the full recording to gain an in-depth understanding of optimizing channel strategy in the CGT landscape. Discover how to effectively navigate the challenges and unlock opportunities in the transformative world of cell and gene therapy.
Related resources
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.